ADMA · Investment summary · as of 12 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
The business does not meet the quality standard for its economic type.
At $9.90, ADMA requires a 7% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 8%.
The value rests on an exit multiple of 10.5x, a terminal operating margin of 35% and a 8.8% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Erosion of ASCENIV's price premium by the mechanism that destroyed BIVIGAM's economics: sustained IG oversupply compresses the late-line premium toward standard-IG level; 73% of revenue through two distributors holds the pricing power; 42% EBIT margin converges on plasma peers (13.5-16.5%).
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Declared A FOR INSTRUMENT PURPOSES (fix underwritten margin, solve price-implied growth, show the surface) with the taxonomy gap disclosed: ADMA literally fails A's >=5y low-variance clause (EBIT negative before FY2023) and no-regime-change clause (loss->profit 2023-24; growth->no-growth 6 May 2026), fails B (no exogenous commodity cycle), fails C (42.3% clean TTM EBIT margin is not thin), fails D ($512m revenue, 64.7% GM). |
| What do we forecast? | Revenue growth of 8% demonstrated; a terminal operating margin of 35%; an exit multiple of 10.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +0.9 percentage points. |
| What is it worth? | Twelve-month target $10.93, +10% from the struck price. Scenario-weighted expected return net of costs +10.4%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| first tested Q3 2026 (~Nov 2026), then every quarter | ASCENIV revenue, 10-Q/8-K product disaggregation | Neither leg of the condition opposite is met at this date | ASCENIV quarterly revenue YoY growth below +10% in any quarter |
| Q3 2026 print (~Nov 2026); FY print (~Feb 2027) | 8-K guidance updates; FY2026 10-K revenue | FY2026 revenue guidance cut at or above $530m, or FY2026 actual below $530m | FY2026 revenue guidance cut below $530m, or FY2026 actual below $530m |
| FY2026 10-K, ~Feb 2027 | AR / Q4 revenue x 91.25 from the FY2025 10-K | DSO at or below 100 days at 31 December 2026 | DSO above 100 days at 31 December 2026 |
| any two consecutive quarters from Q3 2026 | 10-Q gross profit / revenue | Gross margin at or above 62% for two consecutive quarters | Gross margin below 62% for two consecutive quarters |
Erosion of ASCENIV's price premium by the mechanism that destroyed BIVIGAM's economics: sustained IG oversupply compresses the late-line premium toward standard-IG level; 73% of revenue through two distributors holds the pricing power; 42% EBIT margin converges on plasma peers (13.5-16.5%).
Estimated probability 12%, against the 14% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $10.93 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Erosion of ASCENIV's price premium by the mechanism that destroyed BIVIGAM's economics: sustained IG oversupply compresses the late-line premium toward standard-IG level; 73% of revenue through two distributors holds the pricing power; 42% EBIT margin converges on plasma peers (13.5-16.5%). |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +0.9 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: erosion of ASCENIV's price premium by the mechanism that destroyed BIVIGAM's economics: sustained IG oversupply compresses the late-line premium toward standard-IG level; 73% of revenue through two distributors holds the pricing power; 42% EBIT margin converges on plasma peers (13.5-16.5%). The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $8.72, which forces an immediate review.